First, similar CTD-ILD studies associated with PF-ILD were notably limited, most of which did not explicitly analyze each disease subtype; second, most patients in our cohort were those with anti-ARS+ and anti-MDA5+, which can be supported by studies that found approximately a 50% probability of PF-ILD in anti-MDA5+ DM (20). Here, IFIH1 is linked to interstitial lung disease.